BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

AI Meets CRO: Expecto Health Science Partners with VertisPro to Overcome Patient Recruitment Challenges

August 25, 2025 | News

By integrating VertisPro's AI-powered recruitment platform with Expecto's clinical operations expertise, the collaboration aims to accelerate enrolment in oncology and rare disease studies, improving trial efficiency and patient access across the region.



Expecto Health Science, an emerging Asia-Pacific Contract Research Organisation (CRO) led by a highly experienced leadership team, announced a strategic collaboration with VertisPro, a leader in AI-driven patient acquisition solutions.

Expecto is known for its strengths in regulatory strategy, clinical trial planning and management across oncology, infectious diseases, medical devices, and cosmetic research. However, patient recruitment particularly in rare disease and oncology trial remains one of the most significant challenges facing sponsors in the region.

Through this partnership, Expecto will integrate VertisPro's advanced AI recruitment solution into its service offering, enabling sponsors to:

- Identify eligible patients with greater accuracy
- Shorten recruitment timelines
- Improve overall trial enrolment success rates

"The best collaborations happen when both parties bring complementary strengths," said Dr. Pramod Kashid, CEO of Expecto Health Science. *"Our operational expertise now pairs with VertisPro's proven recruitment technology, ensuring sponsors have the tools and support needed to meet enrollment targets efficiently."*

VertisPro's platform uses artificial intelligence to streamline patient identification and engagement, providing sponsors with real, measurable improvements in recruitment performance.

"This partnership combines Expecto's deep clinical operations knowledge with our technology to deliver tangible value to sponsors," said VertisPro CEO Mr. Harshad Puppalwar . *"Together, we aim to set a new benchmark for recruitment efficiency in clinical trials."*

The collaboration underscores both companies' shared mission to advance clinical development, improve trial efficiency, and accelerate patient access to innovative therapies.